首页> 外文会议>IFAC Symposium on Biological and Medical Systems >Development and Pilot Trial Results of Stochastic Targeted (STAR) Glycemic Control in a Medical ICU
【24h】

Development and Pilot Trial Results of Stochastic Targeted (STAR) Glycemic Control in a Medical ICU

机译:医疗ICU中随机靶向(星级)血糖控制的开发和试验试验结果

获取原文

摘要

Accurate glycemic control (AGC) is difficult due to excessive hypoglycemia risk. Stochastic TARgeted (STAR) glycemic control forecasts changes in insulin sensitivity to calculate a range of glycemic outcomes for an insulin intervention, creating a risk framework to improve safety and performance. An improved, simplified STAR framework was developed to reduce light hypoglycemia and clinical effort, while improving nutrition rates and performance. Blood glucose (BG) levels are targeted to 80 - 145mg/dL, using insulin and nutrition control for 1-3 hour interventions. Insulin changes are limited to +3U/hour and nutrition to ±30% of goal rate (minimum 30%). All targets and rate change limits are clinically specified and generalizable. Clinically validated virtual trials were run using clinical data from 371 patients (39,841hours) from the SPRINT cohort. Cohort and per-patient results are compared to clinical SPRINT data. Performance was measured as time within glycemic bands, and safety by patients with severe (BG<40mg/dL) and mild (%BG<72mg/dL) hypoglycemia. Pilot trial results from the first 10 patients (1,458 hours) are included to support the in-silico findings. In both virtual and clinical trials, mild hypoglycemia was below 2% versus 4% for SPRINT. Severe hypoglycemia was reduced from 14 (SPRINT) to 6 (STAR), and 0 in the pilot trial. BG results tighter than SPRINT clinical data, with 91.6% BG within the specified target (80-145mg/dL) in virtual trials and 89.4% in pilot trials. Clinical effort (measurements) was reduced from 16.1/day to 11.8/day (13.5/day in pilot trials). This STAR framework provides safe, accurate glycemic control with significant reductions in hypoglycemia and clinical effort due to stochastic forecasting of patient variation - a unique risk-based approach. Initial pilot trials validate the in silico design methods and resulting protocol, all of which can be generalized to suit any given clinical environment.
机译:由于过量的低血糖风险,准确的血糖控制(AGC)很困难。随机靶向(星级)血糖控制预测胰岛素敏感性的变化来计算胰岛素干预的一系列血糖结果,从而创造了提高安全性和性能的风险框架。改进了简化的明星框架,开发了降低轻血糖和临床努力,同时提高营养率和性能。使用胰岛素和营养控制血糖(BG)水平靶向80-145mg / dL,持续1-3小时干预。胰岛素的变化限制为+ 3U /小时,营养率达到目标率的±30%(最小30%)。所有目标和速率变化限制都是临床指定和更广泛的。临床验证的虚拟试验使用来自Sprint Cohort的371名患者(39,841小时)的临床数据进行运行。将群组和每患者结果与临床冲刺数据进行比较。在血糖带内的时间测量性能,以及严重(BG <40mg / dL)和轻度(%BG <72mg / DL)低血糖的患者的安全性。包括前10名患者(1,458小时)的试验试验结果,以支持硅藻体。在虚拟和临床试验中,Sprint的轻度低血糖低于2%而不是4%。严重的低血糖从14点(Sprint)降低至6(星),并在试验试验中减少0。 BG结果比Sprint临床数据更紧密,在指定的目标(80-145mg / dl)中,虚拟试验中的91.6%BG,试验中的89.4%。临床努力(测量)从16.1 /天到11.8 /天(试验试验中的13.5 /天)减少。该明星框架提供了安全,准确的血糖控制,由于患者变异的随机预测,由于对患者变化的随机预测而显着降低了低血糖和临床努力 - 一种独特的基于风险的方法。初始试验试验验证了Silico设计方法和所产生的协议,所有这些都可以推广以适应任何给定的临床环境。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号